Mei Z, Zhang K, Lam AKY, et al. - Since the modification of chimeric antigen receptor (CAR) endowing T cells with tumor-specific cytotoxicity induces antitumor immunity, however, the structural characteristics of solid tumors, the loss of specific antigens, and the strong immunosuppressive environment are challenges to treat solid tumors with CAR-T therapy, researchers sought to discover and confirm the potentials of CAR-T therapies for head and neck squamous cell carcinoma (HNSCC) patients. For patients with HNSCC with MUC1 expression, the designed fourth-generation humanized MUC1 CAR-T cells give excellent preclinical studies. Such results could design safer and more effective CAR-T cells for potential delivery of the best treatment for HNSCC patients.